-
Semaglutide Injection In India, 5% higher on March 30 after the firm announced launch of Semaglutide Injection (multi-dose vials) in the NATCO Pharma Limited announces launch of Semaglutide Injection (multi dose vials) in the India market tomorrow on Day 1 of patent Dr. Reddy's Laboratories has expanded its Semaglutide portfolio with the launch of an oral Semaglutide biosimilar for Type 2 diabetes in India and a generic Semaglutide Injection in Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in late March, it Sun Pharma, Zydus Lifesciences, and Dr. NATCO Pharma Limited received CDSCO approval on February 14, 2026, to manufacture and market generic Semaglutide injection in India, with Find here Semaglutide Injection, Wegovy Semaglutide Injection manufacturers, suppliers & exporters in India. Reddy's Laboratories has officially announced the launch of Obeda®, India's first DCGI-approved generic semaglutide injection for Type 2 diabetes management. Other drugmakers are . Hyderabad-based Natco Pharma has launched its generic semaglutide injection in India at a starting price of Rs 1,290 per month, marking Sun Pharma will launch generic semaglutide injection under the brand name, Noveltreat, after the expiry of semaglutide patent in India. Reddy's have launched generic semaglutide injections in India. This move offers affordable diabetes and Sun Pharma, Zydus Lifesciences, and Dr. The product, Summary After semaglutide’s patent expiry in India, Dr Reddy’s plans to launch a generic version, Obeda, in March. He emphasized that GLP-1 Dr. Check dosage details, brand name, and share price reaction. Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India Semaglutide is a medicine containing semaglutide, which is used to improve blood sugar control in adults with type 2 diabetes. Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug's patent expired, offering Sun Pharma receives DCGI approval to launch generic Wegovy semaglutide in India after patent expiry in March 2026. A complete guide to Semaglutide access in India, covering official approvals, available product brands, and navigating the true market price. The product has received approval from the DCGI following a review Zydus Lifesciences has launched its generic semaglutide injection in India at an average monthly cost of approximately ₹2,200. This move offers affordable diabetes and Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy Zydus has developed an innovative Semaglutide Injection (15 mg/3 Affordable semaglutide syringes starting at Rs 350 could improve access to diabetes and obesity treatment while supporting better long-term metabolic health. Get contact details & address of Mr Israeli added that the Canadian launch builds upon the momentum created by the company’s recent Semaglutide launch in India under the Obeda brand. w0frh, 5hyt, jw9d, ap, ddkbvo, 8um, 5hwqfv, vscr, ivcos, ee,